Novel Protein Adjuvant for Flu Vaccines

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$600,000.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI085783-01A1
Award Id:
95740
Agency Tracking Number:
AI085783
Solicitation Year:
n/a
Solicitation Topic Code:
NIAID
Solicitation Number:
n/a
Small Business Information
1379 Dilworthtown Xing #117, West Chester, PA, -
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
623491748
Principal Investigator:
JIUJIANG
() -
Business Contact:
XINFAN
() -
info@dmxbio.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): Vaccination plays a major role in the control of seasonal influenza virus infection. In addition to the morbidity and mortality associated with annual influenza virus epidemics, there is an ever-present threat of the e mergence of a global pandemic. It is estimated that a vaccine to a new pandemic strain produced using the current system of egg-based vaccine production would not be available for at least six months after the pandemic arises. Over the last three decades, speed, efficiency, and capacity of recombinant protein production have been greatly improved, providing new opportunities for generation of vaccines based on recombinant, purified antigens. In contrast to traditional vaccines that primarily consist of live attenuated or inactivated whole pathogens, new generation vaccines offer the promise of more specific immune protection with less adverse effects. However, these subunit antigens are less immunogenic and the lack of an effective adjuvant suitable for huma n use has severely limited the development of subunit vaccines. We have identified a protein from the helminth parasite Onchocerca volvulus, named O. volvulus activation-associated secreted protein-1 (Ov-ASP-1) that has intrinsic immunostimulatory prope rties. In preliminary studies, we have demonstrated that recombinant Ov-ASP-1 is a powerful immunostimulatory adjuvant, which stimulates both antibody and cellular responses to a number of model antigens. Our protein adjuvant has a potential advantage beca use it is a natural protein secreted from a parasite and it does not induce any pathological outcomes. In this SBIR Phase I application, we will test the use of rOv- ASP-1 as an adjuvant for the development of flu vaccines that may overcome the shortcoming s of current flu vaccine technology. PUBLIC HEALTH RELEVANCE: Vaccination plays a major role in the control of seasonal influenza virus infection. It is estimated that a vaccine to a new pandemic strain produced using the current system of egg-based va ccine production would not be available for at least six months after the pandemic arises, therefore new methods for rapidly synthesizing vaccines are needed. We have identified a protein (rOV-ASP-1) that has intrinsic immunostimulatory properties. In prel iminary studies, we have demonstrated that recombinant Ov-ASP-1 is a powerful immunostimulatory adjuvant, which stimulates both antibody and cellular responses to a number of model antigens. In this SBIR Phase I application, we will test the use of rOv-ASP - 1 as an adjuvant for the development of flu vaccines that may overcome the shortcomings of current flu vaccine technology.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government